Webinar: Children Are Not Small Adults – Importance of Biopharmaceutics and Dose Design in Pediatric Drug Development
Date: Tuesday, April 27, 2021
Time: 4PM London/ 11AM New York
Over the years, tremendous efforts have been made by regulators to incentivize pharmaceutical companies to develop medicines specifically for the pediatric population. However, developing drug products for pediatric populations is a challenging undertaking due to the physiological differences between children and adults. This complexity is further compounded with the requirement of age appropriate dosage forms.
Join this webcast to hear a distinguished speaker discuss the current challenges in pediatric drug development programs including predicting oral absorption, and in vitro and in silico methods that can be applied to predict behavior in pediatric populations. During this session, a Catalent expert will highlight formulation and dosage form development strategies based on target product profiles that can help bring patient centric treatments to market faster.
- Learn about current challenges in predicting oral absorption in pediatric populations
- Explore biorelevant age appropriate in vitro and in silico methods for pediatric drug development
- Discover formulation development strategies and dose form presentation based on target product profiles for pediatric patients
- Understand how dose form manufacturing capabilities are scaled to meet pediatric clinical trial and market requirements
Professor Hannah Batchelor, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow
Dr. Andrew Parker, Director Open Innovation, Small Molecules, Oral and Specialty Drug Delivery, Catalent Pharma Solutions